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September 11, 2012:1027–30diac source of increased circulating concentrations of cardiac
troponin T” by Jaffe et al. (2) published in the October 2011
ssue of the Journal. In their letter, Sribhen et al. (1) share their
experience on a case of a 27-year-old man experiencing severe
rhabdomyolysis after abdominal surgery due to intestinal her-
niation with bowel gangrene. Initially, this patient showed a
concordant increase in the third-generation cardiac troponin T
(cTnT) and cTnI assays on the third post-operative day with a
consecutive fall in cTnT and cTnI levels. Subsequently, the
cTnI level decreased to reference ranges, whereas the cTnT
level began to rise again, reaching a maximum on the 18th
post-operative day. Based on the report of Jaffe et al. (2), the
esearchers argued that these findings support the hypothesis
hat the re-elevation of the cTnT level might be the conse-
uence of re-expression of cTnT isoforms in skeletal muscle
uring the subacute phase of rhabdomyolysis. In support of
heir hypothesis, the researchers argued that a higher rate of
levations in cTnT level as compared with cTnI level is also
ound in end-stage renal disease (3) and quoted reports on
ross-reactivity of the first-generation TnT assay (4).
In our view, this interpretation is neither substantiated by their
data nor the data provided by Jaffe et al. (2) in the original paper
or his comments accompanying this letter.
First, extensive testing during development of the cTnT assay
showed no false positive cTnT elevations, even in patients with
severe skeletal muscle injury and extremely high blood creatine
kinase activity.
Second, in the particular patient reported by Sribhen et al. (1),
here are many possible reasons for elevations in cTnT and cTnI
evels on the third post-operative day, such as post-operative
yocardial infarction, acute renal failure, systemic inflammatory
esponse syndrome due to intestinal gangrene, and pulmonary
mbolism, to name only a few. These established causes of
roponin release are—in our opinion—a much more likely expla-
ation for the cTnT elevations than re-expression of cTnT
soforms in skeletal muscle. There have been no scientific data yet
ndicating re-expression of cTnT in skeletal muscle in severely
iseased patients in the intensive care setting.
Third, the reasons for the discordant findings of cTnI and
TnT are unclear, and the limited clinical information provided
y Sribhen et al. (1) does not contribute to clarification. Several
actors may interfere with the cTnI measurements, causing a
alse negative result, such as hemolysis, heparin interference,
utoantibodies, heterophilic antibodies, and a lower analytical
ensitivity and precision of the third-generation cTnI versus
TnT assay (5).
The observation of cTnT, and less often cTnI, elevations in
ome patients with skeletal muscle myopathy or dystrophy is
nteresting and most likely explained by myocardial involvement
ue to a systemic disorder. Nevertheless, the possibility of
e-expression of cTnT in skeletal muscle merits thorough
cientific evaluation. However, the study cohort reported by
affe et al. (2), which is used in support of the case, is subject to
n inherent inclusion bias because only those patients who were
TnI negative but cTnT positive were included in the trial. So
ar, no data are available in an unselected population with
keletal muscle diseases. In their paper published in the Journal,
affe et al. (2) concluded that they found the “same molecular
eight proteins in diseased skeletal muscle and in the heart.”
owever, looking closer at the figures revealed that immuno-eactive proteins in the diseased skeletal muscle detected byWestern blotting had a different molecular weight as compared
with cTnT in heart muscle (Fig. 2 of their article). For the
soleus muscle extract, 2 peptides were heavily stained using the
monoclonal cTnT antibody M7, and these peptides had mo-
lecular weights much lower than cTnT (Fig. 3 of their article).
Interestingly, the skeletal muscle samples were not probed for
cTnI re-expression. Thus, it is impossible to prove the re-
expression of troponin T in skeletal muscle by these experiments.
Only sequencing of the proteins that were stained by the antibod-
ies in the Western blot would clarify if indeed a cTnT fragment or
much more likely unspecific binding of the antibodies in tissue
sections could explain the staining in the Western blot.
We believe that interpretation of elevated cTn concentrations,
particularly when more sensitive assays are used, has become a
challenging task for clinicians. However, the case by Sribhen et al.
(1) and the explanations provided by Jaffe et al. (2) are not
substantiated by robust scientific data and therefore will not aid in
explaining the TnT elevations in this complex case.
There is a large database indicating that elevation of cTns in the
absence of acute coronary syndrome, commonly mislabeled as a
false-positive cTn result, is an independent predictor of patient
outcome, particularly if myocardial damage is due to a different
mechanism than myocardial ischemia. Thus, so far there are no
robust scientific data supporting the hypothesis that re-expression
of cTnT in skeletal muscle may be a reasonable explanation for
elevated TnT levels in critical care.
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Reply
We thank Drs. Giannitis and Katus for their interest in our paper
(1) concerning the clinical specificity of cardiac troponin T (cTnT)
R1029JACC Vol. 60, No. 11, 2012 Correspondence
September 11, 2012:1027–30in skeletal muscle disease. Because several parts of their letter also
referred to the article by Jaffe et al. (2), which is beyond the scope
of our discussion, we will respond only to the parts addressing the
results of our study.
Drs. Giannitis and Katus have stated that the re-elevations of
cTnT found in the subacute phase (2 to 4 weeks) of rhabdomy-
olysis in our patient could be due to post-operative myocardial
infarction or pulmonary embolism. However, the patterns of cTnT
release that showed chronic elevations, and not acute rise and fall,
over several weeks are not typical of acute ischemic events. They
also stated that the negative cardiac troponin I (cTnI) results
observed in our study might occur as a result of interference by
certain factors present in the blood samples. In this regard, it is true
that analytic interferences by hemolysis or heterophilic antibodies
may cause false-negative troponin I results (2). Nevertheless, these
interferences can occur in both cardiac troponin assays. In
addition, it is unlikely that hemolysis caused negative troponin
I results in all 5 blood samples that were measured in the
subacute phase of rhabdomyolysis. Furthermore, why should
the interfering effects of heterophilic antibodies occur only in
the subacute phase and not in the acute phase in blood samples
obtained from the same person?
To substantiate the significance of our findings, we report
another patient with chronic renal failure who was receiving
maintenance hemodialysis and developed rhabdomyolysis after
limb ischemia. As in the first index case, there were significant
increases in both creatine kinase myocardial band and cTnT
(third-generation immunoassay; Roche Diagnostics, Basel, Swit-
zerland) from elevated baseline concentrations during the second
to fourth weeks of the acute event, with peak values of approxi-
mately 7-fold the upper limit of reference ranges (personal obser-
vation). During this period, no increase in cTnI (first-generation
immunoassay; Ortho Clinical Diagnostics, Raritan, New Jersey)
serum concentration was observed. Of interest was the observation
by Visvanathan and Visvanathan (3), who reported a female
patient with sepsis-associated rhabdomyolysis exhibiting persistent
elevations of cTnT and creatine kinase myocardial band serum
concentrations throughout her stay in the rehabilitation unit of
more than 2 months. Unfortunately, measurement of cTnI was not
performed. Nonetheless, the authors theorized that the prolonged
elevations of cTnT were most likely due to reexpression of the
cTnT isoform in regenerating skeletal muscle.
In this context, it should be noted that we did not intend to
provide evidence for the reexpression phenomenon with data from
our case study. Rather, the results are hypothesis generating and, in
agreement with Drs. Giannitis and Katus, require thorough
scientific evaluation and confirmation from large studies.
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Multidetector Computed
Tomography for Detecting
Lesions That Are at High Risk
for Myocardial Necrosis
After Percutaneous
Coronary Intervention
Watabe et al. (1) should be commended for their recent study,
which evaluated the impact of coronary plaque composition on
cardiac troponin elevation after percutaneous coronary intervention
in patients with stable angina pectoris. It is a novel approach and
could have important clinical implications. However, a few perti-
nent points should be considered before reaching a final conclu-
sion. First, multidetector computed tomography (MDCT) has
some serious limitations when used for plaque analyses, including
and not limited to, overestimates of plaque volume (especially for
calcified plaques), limited ability to identify thin-cap fibroathero-
mas (vulnerable plaques) due to limited spatial resolution, and a
very high interobserver variation in plaque assessment (2,3). Most
of the studies supporting the ability of MDCT to differentiate
culprit and nonculprit lesions are retrospective and have their
own limitations; moreover, the significance of individual plaque
characterization has been challenged in a large-scale prospective
study (4).
Second, although soft and fibrous plaques cannot be distin-
guished on the basis of computed tomography attenuation, other
features of plaque vulnerability, such as “ring-like enhancement”
on MDCT, have been described (5); it would be interesting to
know if the authors made an attempt to study and include such
features in the current study (1).
Third, difficulties in delineating vessel borders and poor image
quality, especially in obese patients, are other practical aspects that
limit MDCT utility. These limitations, along with the fact that the
current study included only Japanese patients (1), who usually have
lower body mass indices than the typical Western patient, further
limit its direct clinical applicability to Western populations.
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